An Oxford cancer patient who was told she may have only eighteen months to live is free from signs of the disease after taking a trial drug for almost three years. Susan Cakebread received her pioneering treatment at the Early Phase Clinical Trials Unit at Oxford’s Churchill Hospital which aims to discover new treatments for the future.
Dr Sarah Blagden, Associate Professor of Experimental Cancer Therapeutics in the Department of Oncology, has become the Experimental Cancer Medicine Centre (ECMC) lead for Oxford.
Roche has awarded four Early Stage Researchers the Roche Discovery Oncology Award at its Innovation Center in Penzberg near Munich.
National charity Pancreatic Cancer UK has today announced the award of £100,000 to a research team based at the University of Oxford. The grant will allow the addition of a new member to the team as part of the charity’s pioneering Future Leaders Fund, amounting to over £500,000 in similar grants across the UK. This award will support a student through a DPhil project which will be supervised by Dr Emmanouil Fokas and Professor Eric O’Neill.
Dr Avinash Gupta, final year Medical Oncology Registrar and Early Phase Trials Clinical Research Fellow in the Department of Oncology, has been awarded the Association of Cancer Physicians McElwain Prize for 2015 for his work on melanoma.
Scientists have discovered a protein that helps map the edge of brain tumours more clearly so they show up on magnetic resonance imaging (MRI) scans, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
The laboratory research, carried out in rats, could lead to clinical trials aimed at improving the accuracy of brain tumour treatment.
It is well known that mutations drive cancer cell growth and resistance to treatment. However, these mutations can also become a weak point, or Achilles’ heel, for a tumour. Now, scientists at the University of Oxford have found a new way to kill cancer cells with mutations in a key cancer gene called SETD2.
One of the areas of expertise in Oxford is radiation biology - the impact of radiation on living cells. The damage radiation does to cells is brought about by the damage caused to DNA. Scientists in the Department of Oncology and the CRUK/MRC Oxford Institute for Radiation Oncology in Oxford, are focusing their work on understanding how cells repair that damage.
On 5 September Professor Nicola Sibson and Dr Ester Hammond from the Department of Oncology, donned their running gear and took part in the Cancer Research UK Race for Life Pretty Muddy® event in Windsor.
The pair, who are both group leaders in the CRUK/MRC Oxford Institute for Radiation Oncology, raised over £1000 for Cancer Research UK by running the 5K muddy obstacle course at Olympic venue Dorney Lake. The course included cargo nets, jumps, walls, slides and crawls with the added challenge of being covered in mud.
Cancer Research UK and the Medical Research Council (MRC) have jointly launched a Stratified Medicine Consortium to help personalise bowel cancer treatment by matching patients to the most effective therapies.